Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PASSIGLIA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.993
EU - Europa 2.169
AS - Asia 2.049
Continente sconosciuto - Info sul continente non disponibili 359
SA - Sud America 325
AF - Africa 39
OC - Oceania 6
Totale 11.940
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.886
SG - Singapore 805
RU - Federazione Russa 588
CN - Cina 534
IT - Italia 523
BR - Brasile 243
DE - Germania 226
VN - Vietnam 190
FI - Finlandia 188
HK - Hong Kong 180
GB - Regno Unito 143
PL - Polonia 120
FR - Francia 87
IE - Irlanda 87
JP - Giappone 68
KR - Corea 54
CA - Canada 51
SE - Svezia 50
IN - India 48
BD - Bangladesh 29
TR - Turchia 28
IQ - Iraq 25
AR - Argentina 24
UA - Ucraina 23
RO - Romania 22
ES - Italia 21
NL - Olanda 19
BE - Belgio 17
MX - Messico 17
UZ - Uzbekistan 15
CO - Colombia 14
EC - Ecuador 14
VE - Venezuela 13
MA - Marocco 10
CH - Svizzera 9
ID - Indonesia 9
IR - Iran 9
AT - Austria 8
JM - Giamaica 8
PK - Pakistan 8
PY - Paraguay 8
CR - Costa Rica 7
ZA - Sudafrica 7
KE - Kenya 6
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
DK - Danimarca 5
LB - Libano 5
PT - Portogallo 5
SA - Arabia Saudita 5
TW - Taiwan 5
AU - Australia 4
MY - Malesia 4
NI - Nicaragua 4
PA - Panama 4
PH - Filippine 4
UY - Uruguay 4
AL - Albania 3
BG - Bulgaria 3
CL - Cile 3
DZ - Algeria 3
EE - Estonia 3
EG - Egitto 3
GT - Guatemala 3
HN - Honduras 3
IL - Israele 3
NP - Nepal 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
GR - Grecia 2
HR - Croazia 2
KG - Kirghizistan 2
MD - Moldavia 2
MO - Macao, regione amministrativa speciale della Cina 2
NZ - Nuova Zelanda 2
SV - El Salvador 2
AM - Armenia 1
BM - Bermuda 1
BW - Botswana 1
BY - Bielorussia 1
CU - Cuba 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
GP - Guadalupe 1
HU - Ungheria 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
MN - Mongolia 1
NA - Namibia 1
Totale 11.576
Salva come PNG Salva come JPEG
Città #
Fairfield 1.017
Ashburn 717
Singapore 536
Woodbridge 462
Seattle 433
San Jose 429
Cambridge 353
Wilmington 351
Houston 349
Chandler 336
Ann Arbor 195
Hong Kong 173
Council Bluffs 130
Palermo 117
Moscow 112
Zgierz 99
Beijing 97
Helsinki 88
Dublin 82
Medford 82
Los Angeles 81
Santa Clara 81
Nanjing 73
Altamura 69
New York 64
Boardman 61
Chicago 60
Ho Chi Minh City 58
Des Moines 57
Tokyo 56
Lauterbourg 53
Princeton 53
Lawrence 50
San Diego 50
The Dalles 46
Hanoi 42
Dallas 40
Phoenix 37
Saint Petersburg 35
Dearborn 33
Frankfurt am Main 31
Ludwigshafen am Rhein 30
London 29
Hefei 28
Seoul 28
Kitzingen 25
Panama City 25
Buffalo 23
Rome 23
Tianjin 21
Shenyang 20
Atlanta 18
Jinan 18
Hebei 17
Milan 17
Redwood City 17
Brussels 16
Warsaw 16
Orem 15
São Paulo 15
Baghdad 14
Changsha 14
Bremen 13
Da Nang 13
Denver 13
Izmir 13
Jiaxing 13
Nanchang 13
Nuremberg 13
Tulsa 13
Rio de Janeiro 12
Amsterdam 11
Kumar 11
Stockholm 11
Toronto 11
Belo Horizonte 9
Brooklyn 9
Columbus 9
Manchester 9
Ningbo 9
Philadelphia 9
Quito 9
Seongnam 9
Tashkent 9
Zhengzhou 9
Haiphong 8
San Paolo di Civitate 8
Surrey 8
Boydton 7
Casablanca 7
Pune 7
Shanghai 7
Buenos Aires 6
Falls Church 6
Joinville 6
Mexico City 6
Munich 6
San Francisco 6
San José 6
Abidjan 5
Totale 8.066
Salva come PNG Salva come JPEG
Nome #
EGFR inhibition in NSCLC: New findings…. and opened questions? 358
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 355
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 327
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 324
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 320
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 298
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 294
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 293
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression 288
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 283
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 280
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 276
Nintedanib in NSCLC: Evidence to date and place in therapy 264
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 258
Cancer and the microbiome: Potential applications as new tumor biomarker 258
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 253
The role of targeted therapy for gastrointestinal tumors 251
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 241
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer 240
Multisciplinary management of patients with liver metastasis from colorectal cancer 233
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 231
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway 228
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 228
Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC) 226
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 224
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 217
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 211
Liquid biopsies in lung cancer: The new ambrosia of researchers 210
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 210
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 210
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 209
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) 208
Improvement in lung cancer outcomes with targeted therapies: An update for family physicians 204
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 188
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines 187
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 186
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab 179
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 179
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib? 178
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 176
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 173
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 169
Immune-Biomarkers in Advanced Non-Small Cell Lung Cancer 164
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 161
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 161
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 155
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 154
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 153
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 151
Ramucirumab and its use in gastric cancer treatment 147
Upfront radiation versus EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis? 147
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 121
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 116
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 116
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 69
Totale 11.940
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.906
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.906
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022497 0 0 0 24 33 36 31 61 64 81 56 111
2022/2023967 98 206 23 120 100 137 48 70 85 10 47 23
2023/2024366 13 55 32 22 18 63 46 25 5 11 7 69
2024/20251.104 17 120 106 80 32 46 86 107 50 107 128 225
2025/20263.422 293 112 195 270 376 442 506 430 263 247 112 176
2026/2027766 234 117 397 18 0 0 0 0 0 0 0 0
Totale 11.940